Regulation of Angiotensin II Receptor Expression in Ovarian Follicles

1995 ◽  
pp. 407-410 ◽  
Author(s):  
A. H. Nielsen ◽  
A. Hagemann ◽  
B. Svenstrup ◽  
J. Nielsen ◽  
K. Poulsen
Keyword(s):  
Angiotensin Ii ◽  
Ovarian Follicles ◽  
Receptor Expression ◽  
Angiotensin Ii Receptor

Regulation of Angiotensin II Receptor Expression

2013 ◽  
Vol 19 (17) ◽  
pp. 3013-3021 ◽  
Author(s):  
Toshihiro Ichiki
Keyword(s):  
Angiotensin Ii ◽  
Receptor Expression ◽  
Angiotensin Ii Receptor

Myocardial angiotensin II receptor expression and ischemia-reperfusion injury

1998 ◽  
Vol 3 (2) ◽  
pp. 121-130 ◽  
Author(s):  
Baichun Yang ◽  
Dayuan Li ◽  
M Ian Phillips ◽  
Paulette Mehta ◽  
Jawahar L Mehta
Keyword(s):  
Angiotensin Ii ◽  
Reperfusion Injury ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Receptor Expression ◽  
Angiotensin Ii Receptor

scholarly journals Meconium Increases Type 1 Angiotensin II Receptor Expression and Alveolar Cell Death

2008 ◽  
Vol 63 (3) ◽  
pp. 251-256 ◽  
Author(s):  
Charles R Rosenfeld ◽  
Alexander M Zagariya ◽  
Xiao-Tie Liu ◽  
Brigham C Willis ◽  
Steven Fluharty ◽  
...  
Keyword(s):  
Cell Death ◽  
Angiotensin Ii ◽  
Receptor Expression ◽  
Angiotensin Ii Receptor ◽  
Alveolar Cell

scholarly journals Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression

2009 ◽  
Vol 89 (2) ◽  
pp. 164-177 ◽  
Author(s):  
Akiko Mii ◽  
Akira Shimizu ◽  
Yukinari Masuda ◽  
Masamichi Ishizaki ◽  
Hiroshi Kawachi ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Receptor Expression ◽  
Receptor Blockade ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Blockade

ANGIOTENSIN II RECEPTOR DENSITY IN BOVINE OVARIAN FOLLICLES RELATES TO TISSUE RENIN AND FOLLICULAR SIZE

1994 ◽  
Vol 21 (6) ◽  
pp. 463-469 ◽  
Author(s):  
A. H. Nielsen ◽  
A. Hagemann ◽  
B. Svenstrup ◽  
J. Nielsen ◽  
K. Poulsen
Keyword(s):  
Angiotensin Ii ◽  
Ovarian Follicles ◽  
Receptor Density ◽  
Angiotensin Ii Receptor ◽  
Follicular Size

Difference in the Expression of Hormone Receptors and Fibrotic Markers in the Human Peritoneum—Implications for Therapeutic Targets to Prevent Encapsulating Peritoneal Sclerosis

2011 ◽  
Vol 31 (3) ◽  
pp. 291-300 ◽  
Author(s):  
Niko Braun ◽  
Peter Fritz ◽  
Dagmar Biegger ◽  
Martin Kimmel ◽  
Fabian Reimold ◽  
...  
Keyword(s):  
Vitamin D ◽  
Angiotensin Ii ◽  
Nuclear Receptors ◽  
Hormone Receptors ◽  
Transforming Growth Factor ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Receptor Expression ◽  
Angiotensin Ii Receptor ◽  
Converting Enzyme Inhibitors ◽  
Significant Difference

ObjectiveEncapsulating peritoneal sclerosis (EPS) is a rare but life-threatening complication of peritoneal dialysis (PD). The optimal management of patients with EPS is uncertain. In the present study, we investigated differences in the expression of nuclear receptors [progesterone (PR), androgen (AR), vitamin D (VDR), and glucocorticoid (GCR)] in the human peritoneum. We also investigated estrogen receptor (ER), matrix metalloproteinase 9 (MMP9), and transforming growth factor β1 (TGFβ1) in the context of their potential role in tamoxifen therapy.MethodsWe analyzed clinical and histologic characteristics of 72 peritoneal biopsy specimens (22 from EPS patients, 11 from PD patients, 15 from uremic patients, and 24 from control subjects undergoing hernia repair). For immunophenotyping, we used antibodies against VDR, GCR, ER, PR, AR, MMP9, and TGFβ1.ResultsIn human peritoneum, VDR and GCR are highly expressed (98.6% and 87.3% respectively). Except in the case of VDR ( p = 0.0012), we observed no significant difference in receptor expression between the groups. Expression of ER and PR was sparse (11.4% and 31% respectively), with higher expression in women, and AR was absent. Minimal MMP9 expression and moderate TGFβ1 expression were observed in all groups. The differences between the groups were nonsignificant.ConclusionsNuclear receptors are present in human peritoneum. Except in the case of VDR, the pattern for any one group is nonspecific. Glucocorticoids, vitamin D, and angiotensin converting-enzyme inhibitors or angiotensin II receptor blockers (via the vitamin D/angiotensin II pathway) might be suitable interventions for preservation of the integrity of the peritoneal membrane. The mechanism of action of tamoxifen is still not elucidated, ER expression in the peritoneum is sparse, and data about the studied pathways (MMP9, TGFβ) are inconsistent.

scholarly journals Regulation of Angiotensin II Receptor Expression by Nitric Oxide in Rat Adrenal Gland

Hypertension ◽  
1998 ◽  
Vol 32 (3) ◽  
pp. 527-533 ◽  
Author(s):  
Makoto Usui ◽  
Toshihiro Ichiki ◽  
Makoto Katoh ◽  
Kensuke Egashira ◽  
Akira Takeshita
Keyword(s):  
Nitric Oxide ◽  
Angiotensin Ii ◽  
Adrenal Gland ◽  
Receptor Expression ◽  
Angiotensin Ii Receptor

Modulation of Angiotensin II Receptor Expression during Development and Regression of Hypoxic Pulmonary Hypertension

2000 ◽  
Vol 22 (3) ◽  
pp. 323-332 ◽  
Author(s):  
Catherine Chassagne ◽  
Saadia Eddahibi ◽  
Christophe Adamy ◽  
Dominique Rideau ◽  
Françoise Marotte ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Angiotensin Ii ◽  
Receptor Expression ◽  
Angiotensin Ii Receptor ◽  
Hypoxic Pulmonary Hypertension
Sign in / Sign up

Export Citation Format

Share Document